AstraZeneca

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

CEO

Pascal Soriot

CEOPascal Soriot

Employees

94,300

Employees94,300

Headquarters

Cambridge, Cambridgeshire

HeadquartersCambridge, Cambridgeshire

Founded

1992

Founded1992

Employees

94,300

Employees94,300

AZN Key Statistics

Market cap

223.57B

Market cap223.57B

Price-Earnings ratio

28.89

Price-Earnings ratio28.89

Dividend yield

2.10%

Dividend yield2.10%

Average volume

5.53M

Average volume5.53M

High today

$72.52

High today$72.52

Low today

$71.99

Low today$71.99

Open price

$72.50

Open price$72.50

Volume

3.06M

Volume3.06M

52 Week high

$87.68

52 Week high$87.68

52 Week low

$61.24

52 Week low$61.24

AZN News

Benzinga 3d

AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma

On Friday, AstraZeneca Plc AZN reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials assessed...

TipRanks 3d

AstraZeneca announces KALOS, LOGOS trials met all primary endpoints

Results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s (AZN) fixed-dose triple-combination therapy Bre...

TipRanks 4d

AstraZeneca Director Invests in Company Shares

AstraZeneca ( (GB:AZN) ) just unveiled an announcement. AstraZeneca announced that Karen Knudsen, a Non-Executive Director, purchased 1,400 American Depositary...

Analyst ratings

91%

of 32 ratings

Buy

90.6%

Hold

9.4%

Sell

More AZN News

TipRanks 6d

AstraZeneca’s Strong EPS Performance and Strategic Developments Justify Buy Rating

Leerink Partners analyst Andrew Berens has maintained their bullish stance on AZN stock, giving a Buy rating yesterday. Andrew Berens has given his Buy rating...

Seeking Alpha 6d

AstraZeneca discontinues Truqap trial in castration-resistant prostate cancer

AstraZeneca (NASDAQ:AZN) said on Tuesday it will discontinue its late stage trial testing Truqap combination in patients with metastatic castration-resistant pr...

Benzinga 6d

AstraZeneca Q1 Earnings Rise, But China Drug Allegations May Lead To $8 Million Penalty

AstraZeneca Plc AZN on Tuesday reported first-quarter 2025 sales of $13.59 billion, up 7% year over year (+10% at constant currency), slightly missing the conse...

TipRanks 7d

AstraZeneca announces Calquence with venetoclax recommended for approval in EU

A fixed-duration regimen of AstraZeneca’s (AZN) Calquence in combination with venetoclax, with or without obinutuzumab, has been recommended for approval in the...

Seeking Alpha 7d

AstraZeneca warns of potential additional tax penalties in China

AstraZeneca (NASDAQ: NASDAQ:AZN) said Tuesday it could be fined up to $8 million by Chinese authorities over allegedly unpaid import taxes. Concerning the ille...